United States Psoriatic Arthritis Therapeutics Market 2031 | Growth Drivers, Key Players & Investment Opportunities

Market Size and Growth

The Global Psoriatic Arthritis Therapeutics Market is expected to grow at a CAGR of 8.5% during the forecast period (2024-2031).

Get a Free Sample PDF Of This Report (Get Higher Priority for Corporate Email ID):- https://www.datamintelligence.com/download-sample/psoriatic-arthritis-therapeutics-market?sb

Key Development:

United States: Recent Psoriatic Arthritis Therapeutics Developments

✅ In December 2025, positive momentum in biosimilar markets (including inflammatory disease biosimilars relevant to PsA) continued in the US with increasing regulatory activity aimed at expanding access to cost‐effective options for chronic inflammatory conditions like psoriatic arthritis.

✅ In Late 2025, companies continued strategic regulatory submissions for expanded indications and label updates (e.g., supplemental applications citing structural damage data) for leading PsA biologics to broaden clinical labeling and usage.

✅ In November 2025, new long‐term Phase 3b data for TREMFYA® (guselkumab) showed sustained improvement in signs and symptoms of active psoriatic arthritis through Week 48, with continued inhibition of structural joint damage reinforcing its structural‐protective role in PsA treatment.

✅ In November 2025, findings from the APEX trial confirmed that guselkumab delivered durable radiographic protection and deeper clinical responses in active PsA patients, suggesting potential benefit as an early structural‐sparing therapy.

Japan: Recent Psoriatic Arthritis Therapeutics Developments
✅ In December 2025, Samsung Bioepis received marketing approval in Japan for Ustekinumab BS (a biosimilar to Stelara) in 45 mg syringes, expanding accessible biologic options for PsA treatment in the Japanese market.

✅ In October 2025, risankizumab (an IL‐23 inhibitor) had its additional approval application accepted in Japan for expanded dosing in pediatric patients with conditions including psoriatic arthritis, moving it closer to broader use in younger populations.

✅ In October 2025, AbbVie's risankizumab was also designated as a rare disease drug for pediatric pustular psoriasis highlighting ongoing clinical and regulatory interest in IL‐23 pathway therapeutics for inflammatory conditions related to PsA.

✅ In September 2025, a biosimilar ustekinumab injection (developed by Biocon Biologics and marketed by a Japanese partner) continued distribution following its earlier 2025 launch, offering another cost‐effective biologic for managing psoriatic arthritis in Japan.

Buy Now & Unlock 360° Market Intelligence: https://www.datamintelligence.com/buy-now-page?report=psoriatic-arthritis-therapeutics-market

Europe: Recent Psoriatic Arthritis Therapeutics Developments

✅ In December 2025, the European Medicines Agency (EMA) issued a positive CHMP opinion recommending approval for the golimumab biosimilar Gotenfia®, supporting expanded biosimilar options for adults with psoriatic arthritis and other chronic immune‐mediated conditions.

✅ In Late 2025, European regulatory discussions and biosimilar approvals (including ustekinumab biosimilars and golimumab biosimilars) signaled continued diversification of the PsA therapeutic landscape across biologic and biosimilar treatment options.

✅ In November 2025, SteQeyma (a biosimilar to ustekinumab/Stelara) advanced with a CHMP positive opinion covering both plaque psoriasis and psoriatic arthritis indications, highlighting Europe's biosimilar strategy to improve access and reduce treatment costs.

✅ In October-November 2025, updated APEX Phase 3b data presented in Europe reinforced the structural benefit of guselkumab (TREMFYA®) in inhibiting joint damage progression in active psoriatic arthritis, providing robust evidence for its use across PsA domains.

Key Players:

=> AbbVie, Inc., Janssen Biotech, Inc., Novartis AG, Amgen, Inc., Celgene Corporation, Pfizer, Inc., Eli Lilly and Company, UCB, Inc., Biogen Inc., Bristol-Myers Squibb Company.

Speak to Our Analyst and Get Customization in the report as per your requirements: https://www.datamintelligence.com/customize/psoriatic-arthritis-therapeutics-market?sb

Key Segments:

By Drug Class

Nonsteroidal Anti-Inflammatory Drug (NSAID) - ~35% share

Widely prescribed for pain relief, inflammation, and symptomatic management of arthritis.

Disease-Modifying Antirheumatic Drugs (DMARDs) - ~40% share

Includes Antimalarials and Corticosteroids; used to slow disease progression in rheumatoid arthritis and other autoimmune disorders.

Biologic Drugs - ~25% share

TNF-alpha inhibitors, IL-inhibitors, T-cell inhibitors; fastest-growing segment due to targeted therapy, higher efficacy, and increasing adoption in moderate-to-severe cases.

By Route of Administration

Oral - ~50% share

Most common route for NSAIDs and DMARDs; preferred for ease of use in chronic therapy.

Parenteral - ~30% share

Mainly used for biologics and severe cases requiring intravenous or subcutaneous administration.

Topical - ~20% share

Used for localized inflammation management; limited but growing with innovative formulations.

By Distribution Channel

Hospital Pharmacies - ~45% share

Primary channel for biologics and severe case treatments; ensures proper handling and administration.

Retail Pharmacies - ~35% share

Major channel for NSAIDs and oral DMARDs; convenience and accessibility drive growth.

Online Pharmacies - ~20% share

Rapidly growing due to telemedicine, e-prescriptions, and digital healthcare adoption.

By Region

North America - ~35% share

High adoption of biologics, strong healthcare infrastructure, and supportive insurance coverage.

Latin America - ~8% share

Emerging market; growth driven by increasing healthcare access and awareness.

Europe - ~30% share

Strong market for biologics and DMARDs; regulatory support for advanced therapies.

Asia Pacific - ~22% share

Fastest-growing region due to rising prevalence of arthritis, increasing healthcare expenditure, and expanding retail and online pharmacy networks.

Middle East & Africa - ~5% share

Moderate growth driven by hospital-based treatments and urban healthcare expansion.

FAQ

Q: What is the growth rate of the Psoriatic Arthritis Therapeutics Market?

A: The market is projected to expand at a compound annual growth rate (CAGR) of 8.5% during the forecast period from 2024 to 2031.

Unlock 360° Market Intelligence with DataM Subscription Services: https://www.datamintelligence.com/reports-subscription?sb

Power your decisions with real-time competitor tracking, strategic forecasts, and global investment insights all in one place.

✅ Competitive Landscape
✅ Sustainability Impact Analysis
✅ KOL / Stakeholder Insights
✅ Unmet Needs & Positioning, Pricing & Market Access Snapshots
✅ Market Volatility & Emerging Risks Analysis
✅ Quarterly Industry Report Updated
✅ Live Market & Pricing Trends
✅ Import-Export Data Monitoring

Have a look at our Subscription Dashboard: https://www.youtube.com/watch?v=x5oEiqEqTWg?sb

Contact Us -

Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About Us -

DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.

Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.